2020
OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome
Carpenter T, Miller P, Weber T, Peacock M, Insogna K, Kumar R, Luca D, Cimms T, Roberts M, de Beur S. OR29-06 Burosumab Improves Biochemical, Skeletal, and Clinical Features of Tumor-Induced Osteomalacia Syndrome. Journal Of The Endocrine Society 2020, 4: or29-06. PMCID: PMC7208350, DOI: 10.1210/jendso/bvaa046.403.Peer-Reviewed Original ResearchTumor-induced osteomalaciaCutaneous skeletal hypophosphatemia syndromeSerious adverse eventsAdverse eventsSerum phosphorusBone biopsyPhysical functioningMean physical component summary scoreOpen-label phase 2 studyPhysical component summary scoreOsteoid volume/bone volumeSurface/bone surfaceProximal muscle functionBrief Pain InventoryOsteoid surface/bone surfacePhase 2 studyComponent summary scoresTmP/GFRCrest bone biopsiesRenal phosphate wastingHuman monoclonal antibodyMineralization lag timeQuality of lifeExcess FGF23Bone scan
2019
OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome
De Beur S, Miller P, Weber T, Peacock M, Insogna K, Kumar R, Luca D, Theodore-Oklota C, Lampl K, San Martin J, Carpenter T. OR13-1 Burosumab Improves the Biochemical, Skeletal, and Clinical Symptoms of Tumor-Induced Osteomalacia Syndrome. Journal Of The Endocrine Society 2019, 3: or13-1. PMCID: PMC6554835, DOI: 10.1210/js.2019-or13-1.Peer-Reviewed Original ResearchMineralization lag timeTumor-induced osteomalaciaSerum phosphorusAdverse eventsOsteoid thicknessTumor progressionBone biopsyDose intervalMean physical component summary scoreOpen-label phase 2 studyPP groupPhysical component summary scoreOsteoid volume/bone volumeSurface/bone surfaceMean serum phosphorusPhase 2 studySerious adverse eventsOsteoid surface/bone surfaceComponent summary scoresCrest bone biopsiesMean percentage changeEpidermal nevus syndromeRenal phosphate wastingHuman monoclonal antibodyOS/BS
2018
Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study
Portale A, Imel E, Boot A, Högler W, Linglart A, Padidela R, Hoff W, Whyte M, San Martin J, Carpenter T. Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study. 2018, 264-264. DOI: 10.1542/peds.141.1_meetingabstract.264.Peer-Reviewed Original ResearchOpen-label phase 2 studyPhase 2 studyEffect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study
Portale A, Imel E, Boot A, Högler W, Linglart A, Padidela R, Hoff W, Whyte M, San Martin J, Carpenter T. Effect of krn23, a Fully Human anti-fgf23 Monoclonal Antibody, on Rickets in Children with X-linked Hypophosphatemia (xlh): 40-week Interim Results from a Randomized, Open-label Phase 2 Study. Pediatrics 2018, 141: 264-264. DOI: 10.1542/peds.141.1ma3.264.Peer-Reviewed Original ResearchOpen-label phase 2 studyPhase 2 study
2017
A randomized, open-label Phase 2 study of KRN23, an investigational fully human Anti-FGF23 monoclonal antibody, in children with X-linked Hypophosphatemia (XLH)
Hogler W, Portale A, Imel E, Boot A, Linglart A, Padidela R, van't H, Whyte M, Mao M, Skrinar A, Martin J, Carpenter T. A randomized, open-label Phase 2 study of KRN23, an investigational fully human Anti-FGF23 monoclonal antibody, in children with X-linked Hypophosphatemia (XLH). Bone Abstracts 2017 DOI: 10.1530/boneabs.6.oc26.Peer-Reviewed Original ResearchOpen-label phase 2 studyPhase 2 studyEffects of KRN23, a fully human anti-FGF23 monoclonal antibody, on functional outcomes in children with X-linked hypophosphatemia (XLH): results from a randomized, open-label Phase 2 study
Imel E, Carpenter T, Linglart A, Boot A, Hogler W, Padidela R, van't H, Portale A, Mao M, Skrinar A, San M, Whyte M. Effects of KRN23, a fully human anti-FGF23 monoclonal antibody, on functional outcomes in children with X-linked hypophosphatemia (XLH): results from a randomized, open-label Phase 2 study. Bone Abstracts 2017 DOI: 10.1530/boneabs.6.p063.Peer-Reviewed Original Research
2016
Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study
Padidela R, van't H, Hogler W, Portale A, Imel E, Boot A, Linglart A, Whyte M, Skrinar A, San M, Carpenter T. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study. Endocrine Abstracts 2016 DOI: 10.1530/endoabs.45.oc5.1.Peer-Reviewed Original ResearchOpen-label phase 2 studyPhase 2 studyEffect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study
Linglart A, Carpenter T, Imel E, Boot A, Högler W, Padidela R, Hoff W, Whyte M, Chen C, Skrinar A, Agarwal S, San Martin J, Portale A. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study. Annales D Endocrinologie 2016, 77: 440. DOI: 10.1016/j.ando.2016.07.547.Peer-Reviewed Original ResearchRickets Severity ScoreAdverse eventsQ2W dosingXLH childrenSerum PiMost treatment-related adverse eventsOpen-label phase 2 studyTransient injection site reactionsTreatment-related adverse eventsPhase 2 studySerious adverse eventsInjection site reactionsSerum phosphate levelsRadiographic Global ImpressionSerum Pi concentrationSerum iPTHUrine calciumRenal ultrasoundSite reactionsCare treatmentGlobal ImpressionSeverity scoreKRN23Phosphorus homeostasisShort statureEffect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label Phase 2 study
Imel E, Carpenter T, Boot A, Hogler W, Linglart A, Padidela R, van't H, Whyte M, Agarwal S, Chen C, Skrinar A, Martin J, Portale A. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label Phase 2 study. Bone Abstracts 2016 DOI: 10.1530/boneabs.5.ht6.Peer-Reviewed Original ResearchOpen-label phase 2 studyPhase 2 study